European Generics Need To Climb Into Niches, Huddle Together For Growth
The current situation for Europe’s generic medicines manufacturers is at best uncomfortable due to significant pricing pressures and increasing competition, but the reality is that it is likely to get far worse.
You may also be interested in...
If generics firms were permitted to manufacture and stockpile products ahead of IP expiries, it’s estimated they could add almost €4.5 billion ($6.3 billion) to the EU economy over nine years.
The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.
Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.